ORMDL in metabolic health and disease.

Area of Science:

• Biochemistry
• Metabolic Disease Research
• Lipid Metabolism

Background:

• Obesity is a major risk factor for metabolic diseases.
• Bioactive sphingolipid metabolites and their precursors, like saturated fatty acids, increase in obesity.
• Serine palmitoyltransferase (SPT) is the rate-limiting enzyme in de novo sphingolipid biosynthesis.

Purpose of the Study:

• To review the evidence linking dysregulated sphingolipid metabolism and SPT activity to obesity pathogenesis.
• To discuss the roles of SPT and ORMDL proteins in obesity and metabolic disease.
• To identify knowledge gaps and future research directions, particularly concerning ORMDL3's role.

Main Methods:

• Literature review and synthesis of existing evidence.
• Analysis of the regulatory mechanisms of SPT by ORMDL proteins.
• Discussion of the physiological functions of SPT and ORMDL in metabolic health.

Main Results:

• Dysregulation of sphingolipid metabolism and SPT activity is correlated with obesity.
• ORMDL proteins (ORMDL1-3) negatively regulate SPT activity.
• ORMDL3 is identified as an obesity-related gene, suggesting a specific role in pathogenesis.

Conclusions:

• Sphingolipid metabolism alterations are implicated in obesity and metabolic disease.
• Further research is needed to elucidate the precise functions of ORMDL3 in obesity pathogenesis.
• Understanding SPT and ORMDL regulation is crucial for developing therapeutic strategies for metabolic disorders.